Jade Biosciences, Inc. - 8-K Filing
Jade Biosciences announced interim results from a Phase 1 trial of JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy. The study showed up to 70% sustained reduction in IgA levels at the 700 mg dose with no serious adverse events; safety was consistent across all doses tested (up to 1,400 mg). A Phase 2 trial is ongoing and a potential Phase 3 trial is planned for H1 2027. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $AVTE